Table 1

Baseline characteristics

Secukinumab 2×10 mg/kg n=39Placebo n=20Total N=59
Age37.3 (12.0)38.3 (14.3)37.6 (12.7)
Weight (kg)69.4 (14.0)73.4 (14.6)70.7 (14.2)
Disease duration (years)12.2 (9.4)10.3 (6.5)11.5 (8.5)
Gender (male)24 (61.5%)11 (55.0%)35 (59.3%)
Ethnicity (Caucasian)39 (100.0%)19 (95.0%)58 (98.3%)
CRP (mg/l)
 Median (min, max)6 (1, 80)10 (1, 73)9 (1, 80)
FCP (ng/ml)
 Median (min, max)143 (4, 1866) (n=37)128 (4, 6434) (n=18)143 (4, 6434) (n=55)
 Previous bowel surgery19 (48.7%)3 (15.0%)22 (37.3%)
 Prior TNF blocker therapy7 (17.9%)0 (0.0%)7 (11.9%)
 Concomitant steroids22 (56.4%)13 (65.0%)35 (59.3%)
Concomitant immunosuppressants
 Azathioprine/6-MP9 (23.1%)8 (40.0%)17 (28.8%)
 MTX1 (2.6%)1 (5%)2 (3.4%)
 5-ASA14 (35.9%)7 (35.0%)21 (35.6%)
Antibiotics7 (17.9%)1 (5.0%)8 (13.6%)
  • Data are mean (SD) or number (%) unless otherwise indicated.

  • 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine; CRP, C reactive protein; FCP, faecal calprotectin; MTX, methotrexate; TNF, tumour necrosis factor.